The translatability of ferroptosis-targeted therapies from mice to humans is thus uncertain, for example, whether human LN immune cells exhibit the same ferroptosis susceptibility as mouse models, or if species-specific differences in ferroptosis regulators (e.g., FSP1 vs
Next, the many challenges associated with drug design are discussed and we urge additional research attention to neurotrophins given their demonstrated ability to address several of the pathologies that characterize AD
Montoya JG, Kogelnik AM, Bhangoo M, Lunn MR, Flamand L, Merrihew LE, et al
Based on typical prescribing patterns, two vials are designed to last approximately 2 months